Current partner codePEPTIDESDE
NCT01982240·Phase 3·INTERVENTIONAL

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Status

Completed

Phase

Phase 3

Enrollment

1,394

Locations

189

Results

Posted

Publications

5

Study summary

What the protocol is testing.

The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.

Full detailed description

This is a randomized, 12-week, double-blind, placebo-controlled, study in approximately 1350 adult male and female patients with CIC comparing 2 doses of plecanatide to placebo. The study will be conducted at approximately 180 clinical study sites in the United States (US) and Canada. The primary objective of the study is to evaluate the efficacy and safety of 3.0 and 6.0 mg of plecanatide administered once daily (QD) for 12 weeks in a population of patients with CIC. The study population will include only patients without other causes of constipation or other chronic conditions that could interfere with study assessments. Patients may not take laxatives (with the exception of the study-provided rescue medication, bisacodyl 5mg tablets), or a number of prohibited drugs that are known to cause constipation or diarrhea, during study participation. There are 6 scheduled study visits, including the screening and follow-up visits. The planned duration of participation in this study will be 112 days and up to 155 days, with washout and all visit windows considered.

Interventions

Treatment arms and agents.

DRUG

Plecanatide

Plecanatide tablets QD for 12 weeks

DRUG

Placebo

Matching placebo tablets QD for 12 weeks

DRUG

Bisacodyl

Rescue medication

Timeline

From registration to results.

  1. First posted

    Nov 13, 2013

  2. Study start

    Nov 2013

  3. Primary completion

    Apr 2015

  4. Study completion

    Jun 2015

  5. Results posted

    Mar 21, 2019

  6. Registry updated

    Dec 26, 2019

Outcomes

What the study measures.

Primary outcomes

Number of Durable Overall CSBM Responders , Mean Replacement Approach

Time frame · 12-week Treatment Period

A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, included at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

Secondary outcomes

Change From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach

Time frame · 12-Week Treatment Period

A Complete Spontaneous Bowel Movement (CSBM) was a Bowel Movement (BM) that occurred in the absence of laxative use within 24 hours of the BM and the patient reported a feeling of complete evacuation. A weekly responder had 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week.

Change From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach

Time frame · 12-Week Treatment Period

The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was assessed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period in the BM and Symptom Diary.

Change From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach

Time frame · 12-Week Treatment Period

The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

Change From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach

Time frame · 12-Week Treatment Period

Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
80 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Male or female aged 18-80, inclusive * Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months * Completed a colonoscopy in accordance with AGA colon cancer screening guidelines (5 years), with no clinically significant findings * Willing to maintain a stable diet during the study Exclusion Criteria: * Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for \> 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment * Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable * History of cathartic colon, laxative, enema abuse, or ischemic colitis * Fecal impaction within 3 months of screening * Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain * Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis * Major surgery, stroke or MI within 60 days of screening * Participated in a previous plecanatide clinical trial

Study locations

189 registered sites.

Canada · United States. Showing up to 24 locations stored in the fast local snapshot.

Synergy Research Site

Birmingham, Alabama, United States

Synergy Research Site

Dothan, Alabama, United States

Synergy Research Site

Gulf Shores, Alabama, United States

Synergy Research Site

Huntsville, Alabama, United States

Synergy Research Site

Mobile, Alabama, United States

Synergy Research Site

Mesa, Arizona, United States

Synergy Research Site

Phoenix, Arizona, United States

Synergy Research Site

Phoenix, Arizona, United States

Synergy Research Site

Tempe, Arizona, United States

Synergy Research Site

Tucson, Arizona, United States

Synergy Research Site

Hot Springs, Arkansas, United States

Synergy Research Site

Little Rock, Arkansas, United States

Synergy Research Site

North Little Rock, Arkansas, United States

Synergy Research Site

Anaheim, California, United States

Synergy Research Site

Anaheim, California, United States

Synergy Research Site

Carlsbad, California, United States

Synergy Research Site

Cerritos, California, United States

Synergy Research Site

Chula Vista, California, United States

Synergy Research Site

El Cajon, California, United States

Synergy Research Site

Encinitas, California, United States

Synergy Research Site

Encino, California, United States

Synergy Research Site

Fountain Valley, California, United States

Synergy Research Site

Fresno, California, United States

Synergy Research Site

Hawaiian Gardens, California, United States

Publications

Results and literature.

PMID 37332239Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18.PMID 37162147Rao SSC, Laitman AP, Miner PB Jr. Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide. Clin Transl Gastroenterol. 2023 Jul 1;14(7):e00598. doi: 10.14309/ctg.0000000000000598.PMID 35086735Moshiree B, Schoenfeld P, Franklin H, Rezaie A. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials. Clin Ther. 2022 Jan;44(1):98-110.e1. doi: 10.1016/j.clinthera.2021.11.009. Epub 2022 Jan 25.PMID 32660770Menees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10.PMID 28169285Miner PB Jr, Koltun WD, Wiener GJ, De La Portilla M, Prieto B, Shailubhai K, Layton MB, Barrow L, Magnus L, Griffin PH. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am J Gastroenterol. 2017 Apr;112(4):613-621. doi: 10.1038/ajg.2016.611. Epub 2017 Feb 7.

Primary links

Continue at the source.

Related trials

More studies on Plecanatide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.